‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Key Milestones2 |
|
|---|---|
| Call for patient input posted | May 11, 2017 |
| Patient group input closed | June 30, 2017 |
| Clarification:
- Patient input submission received |
|
| Patient input summary sent for review to patient input groups | July 19, 2017 |
| Patient group comments on input summary closed | July 26, 2017 |
| Clarification:
- Patient input summary feedback received |
|
| Submission received | June 09, 2017 |
| Submission accepted for review | June 23, 2017 |
| Review initiated | June 26, 2017 |
| Draft CDR review report(s) sent to applicant | September 28, 2017 |
| Comments from applicant on draft CDR review report(s) received | October 10, 2017 |
| Redaction requests from applicant on draft CDR review report(s) received | October 17, 2017 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | December 01, 2017 |
| Canadian Drug Expert Committee (CDEC) meeting | December 13, 2017 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | January 02, 2018 |
| Embargo period ended and validation of redacted CDR review report(s) received | January 16, 2018 |
| CDEC Final Recommendation issued to applicant and drug plans | January 23, 2018 |
| CDEC Final Recommendation posted | January 25, 2018 |
| Final CDR review report(s) and patient input posted | February 08, 2018 |
Key Milestones2 | |
|---|---|
| Call for patient input posted3 | May 05, 2017 |
| Patient group input closed3 | June 26, 2017 |
| Clarification: - Patient input submission received | |
| Patient input summary sent for review to patient input groups | July 21, 2017 |
| Patient group comments on input summary closed | July 28, 2017 |
| Clarification: - Patient input summary feedback received | |
| Submission received | June 09, 2017 |
| Submission accepted for review | June 23, 2017 |
| Review initiated | July 05, 2017 |
| Clarification: - Submission temporarily suspended pending receipt of information - Additional information has been received and the temporary suspension of the review has been lifted | |
| Draft CDR review report(s) sent to applicant | October 23, 2017 |
| Comments from applicant on draft CDR review report(s) received | November 01, 2017 |
| Redaction requests from applicant on draft CDR review report(s) received | November 08, 2017 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | December 01, 2017 |
| Canadian Drug Expert Committee (CDEC) meeting | December 13, 2017 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | January 03, 2018 |
| Embargo4 period ended and validation of redacted CDR review report(s) received | January 17, 2018 |
| CDEC Final Recommendation issued to applicant and drug plans | January 24, 2018 |
| CDEC Final Recommendation posted5 | January 26, 2018 |
| Final CDR review report(s) and patient input posted5 | February 05, 2018 |
Key Milestones2 |
|
|---|---|
| Call for patient input posted3 | May 02, 2017 |
| Patient group input closed3 | June 21, 2017 |
| Clarification:
- Patient input submission received |
|
| Patient input summary sent for review to patient input groups | July 25, 2017 |
| Patient group comments on input summary closed | August 01, 2017 |
| Clarification:
- Patient input summary feedback received |
|
| Submission received | May 31, 2017 |
| Submission accepted for review | June 14, 2017 |
| Review initiated | June 15, 2017 |
| Draft CDR review report(s) sent to applicant | September 01, 2017 |
| Comments from applicant on draft CDR review report(s) received | September 13, 2017 |
| Redaction requests from applicant on draft CDR review report(s) received | September 20, 2017 |
| Clarification:
- No redaction requests from applicant received |
|
| CDR review team's comments on draft CDR review report(s) sent to applicant | October 05, 2017 |
| Canadian Drug Expert Committee (CDEC) meeting | October 18, 2017 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | October 30, 2017 |
| Embargo4 period ended and validation of redacted CDR review report(s) received | November 13, 2017 |
| CDEC Final Recommendation issued to applicant and drug plans | November 20, 2017 |
| CDEC Final Recommendation posted5 | November 22, 2017 |
| Final CDR review report(s) and patient input posted5 | December 15, 2017 |
Key Milestones2 |
|
|---|---|
| Call for patient input posted3 | April 26, 2017 |
| Patient group input closed3 | June 15, 2017 |
| Clarification:
- Patient input submission received |
|
| Patient input summary sent for review to patient input groups | June 20, 2017 |
| Patient group comments on input summary closed | June 27, 2017 |
| Clarification:
- No patient input summary feedback received |
|
| Submission received | May 29, 2017 |
| Submission accepted for review | June 12, 2017 |
| Review initiated | June 13, 2017 |
| Draft CDR review report(s) sent to applicant | September 05, 2017 |
| Comments from applicant on draft CDR review report(s) received | September 14, 2017 |
| Redaction requests from applicant on draft CDR review report(s) received | September 21, 2017 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | October 05, 2017 |
| Canadian Drug Expert Committee (CDEC) meeting | October 18, 2017 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | October 31, 2017 |
| Embargo4 period ended and validation of redacted CDR review report(s) received | November 14, 2017 |
| CDEC Final Recommendation issued to applicant and drug plans | November 21, 2017 |
| CDEC Final Recommendation posted5 | November 23, 2017 |
| Final CDR review report(s) and patient input posted5 | December 21, 2017 |
Note: The pCODR Provincial Advisory Group, PAG, has submitted a Request for Advice for the Final Recommendation for this drug and indication originally posted on March 7, 2013. The original axitinib (Inlyta) pCODR review can be found on the Inlyta for metastatic renal cell carcinoma (mRCC) details page: /inlyta-metastatic-renal-cell-carcinoma-mrcc-details.
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Key Milestones2 |
|
|---|---|
| Call for patient input posted3 | April 18, 2017 |
| Patient group input closed3 | June 07, 2017 |
| Clarification:
- Patient input submission received |
|
| Patient input summary sent for review to patient input groups | June 15, 2017 |
| Patient group comments on input summary closed | June 22, 2017 |
| Clarification:
- Patient input submission received |
|
| Submission received | May 16, 2017 |
| Submission accepted for review | May 31, 2017 |
| Review initiated | June 01, 2017 |
| Draft CDR review report(s) sent to applicant | August 21, 2017 |
| Comments from applicant on draft CDR review report(s) received | August 30, 2017 |
| Redaction requests from applicant on draft CDR review report(s) received | September 07, 2017 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | October 05, 2017 |
| Canadian Drug Expert Committee (CDEC) meeting | October 18, 2017 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | October 31, 2017 |
| Embargo4 period ended and validation of redacted CDR review report(s) received | November 14, 2017 |
| CDEC Final Recommendation issued to applicant and drug plans | November 21, 2017 |
| CDEC Final Recommendation posted5 | November 23, 2017 |
| Final CDR review report(s) and patient input posted5 | December 15, 2017 |
Key Milestones2 |
|
|---|---|
| Call for patient input posted3 | March 17, 2017 |
| Patient group input closed3 | May 08, 2017 |
| Clarification:
-Patient input submission received |
|
| Patient input summary sent for review to patient input groups | May 15, 2017 |
| Patient group comments on input summary closed | May 23, 2017 |
| Clarification:
-Patient input summary feedback received |
|
| Submission received | April 24, 2017 |
| Submission accepted for review | May 08, 2017 |
| Review initiated | May 09, 2017 |
| Draft CDR review report(s) sent to applicant | July 31, 2017 |
| Comments from applicant on draft CDR review report(s) received | August 10, 2017 |
| Redaction requests from applicant on draft CDR review report(s) received | August 17, 2017 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | September 08, 2017 |
| Canadian Drug Expert Committee (CDEC) meeting | September 20, 2017 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | October 02, 2017 |
| Embargo4 period ended and validation of redacted CDR review report(s) received | October 17, 2017 |
| CDEC Final Recommendation issued to applicant and drug plans | October 24, 2017 |
| CDEC Final Recommendation posted5 | October 26, 2017 |
| Final CDR review report(s) and patient input posted5 | November 16, 2017 |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.